Vantage logo

Curevac rides the Covid wave

Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.

Vantage logo

Covid-19 stalls biotech flotations

Several young drug developers managed to float in the first quarter, but new issues dried up in March when coronavirus infected the markets. Is the game back on?

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.